Azher Hussain

Azher Hussain

Auto-generated profile, based on publicly available information

Azher Hussain

Merck & Co., Lansdale, Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
WLWenping Li
Wenping Li
YWYuchuan Wang
Yuchuan Wang
TLTalakad G. Lohith
Talakad G. Lohith
ZZZhizhen Zeng
Zhizhen Zeng
LTLing Tong
Ling Tong
ABAnthony S. Basile
Anthony S. Basile
[ 11 C]MK-6884 is an M4R-specific PET tracer for quantifying target engagement in brain and providing insights into AD neuropathology.

1 February 2022 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
JNJesse C. Nussbaum
Jesse C. Nussbaum
AHAzher Hussain
Azher Hussain
BMBennett Ma
Bennett Ma
KMK. Chris Min
K. Chris Min
QCQing Chen
Qing Chen
SSS. Aubrey Stoch
S. Aubrey Stoch
Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies, gefapixant was eliminated primarily by renal excretion of the parent drug. The objective of this study was to assess the disposition of gefapixant in humans. The absorption, metabolism, and excretion profiles of gefapixant were assessed after oral administration of a single dose of [14C]gefapixant to six healthy adult males. Following a single‐oral [14C]gefapixant dose to healthy adult males, the mass balance was achieved, with 98.9% of the administered radioactivity recovered in urine and feces. Elimination of gefapixant occurred primarily via renal excretion of the intact drug (64%); metabolism was a minor pathway of elimination of gefapixant (12% and 2% recovered in urine and feces, respectively). Single‐dose administration of [14C]gefapixant 50 mg was generally well tolerated in healthy adult males. The fraction of the anticipated therapeutic oral dose of gefapixant absorbed is estimated to be at least 78%. Gefapixant is expected to be the major circulating drug‐related material in plasma, and the majority of the dosed drug will be excreted unchanged in urine.

4 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TYTimothy A. Yap
Timothy A. Yap
JBJulie Bullock
Julie Bullock
SCSusan Chong
Susan Chong
MDMegan K. Doyle
Megan K. Doyle
AHAzher Hussain
Azher Hussain
VUVijay V. Upreti
Vijay V. Upreti
The Project Optimus initiative from the FDA introduced a new dose optimization and selection paradigm in oncology drug development. The FDA has outlined approaches to dose optimization for single agents, but multiple oncology drugs are being developed for use in combination with other therapies. Dose optimization in the context of combination drug development is complex and requires a case-by-case approach. It necessitates commitment to the totality of available evidence, leveraging all relevant data on mechanism of action, nonclinical and clinical pharmacology, safety, and principles of model-informed drug development. In this article, we outline key considerations for sponsors and investigators pursuing dose optimization with combinatorial regimens. We illustrate important strategies for dose optimization in the combination setting using a range of hypothetical case examples that represent typical drug development scenarios. Close discussions and collaboration with regulators regarding the optimal approaches to these scenarios will continue to be critical.